The Medicines and Healthcare products Regulatory Agency has appointed Jason Bonander as its next Chief Digital and Technology Officer, with a start date in late May 2026. In the government announcement, the Agency said the hire is intended to strengthen senior leadership as it prepares a new five-year strategy and updates the systems behind medicines and medical devices regulation. Bonander joins from the US Centers for Disease Control and Prevention, where he served as Chief Information Officer. The MHRA presented the appointment as part of a wider effort to make regulation faster, more transparent and better supported by data.
This is more than a senior staffing change. For a regulator such as the MHRA, digital leadership affects how information moves through the organisation, how services are delivered to applicants and how clearly regulatory decisions can be recorded and explained. The government statement places technology capacity alongside regulatory modernisation. In practical terms, the Agency is signalling that future performance will depend not only on scientific assessment, but also on whether its platforms, data systems and internal processes can support timely and auditable decisions.
According to the MHRA, Bonander brings more than 25 years of experience in technology leadership and health informatics. At the CDC, his responsibilities included technology operations, cyber security, public health informatics and data-sharing strategy. That background is relevant to a UK regulator managing increasingly complex information across medicines, devices and newer digital products. The reference to cyber security is also notable, because any attempt to modernise regulatory services depends on secure systems and clear control over sensitive data.
The policy message is clearest in the MHRA’s description of its wider aim: data-driven regulation for medicines, artificial intelligence and advanced technologies, while maintaining firm regulatory standards. That wording suggests an Agency preparing for products that do not sit neatly within older administrative routines. For manufacturers and developers, digital capability shapes how quickly a regulator can review evidence, manage submissions and respond to change. For patients and the wider public, the question is broader. Faster processes matter, but so do transparency, traceability and confidence that safety oversight remains strong.
MHRA Chair Professor Anthony Harnden and chief executive Lawrence Tallon both used the announcement to link technology modernisation with patient protection and confidence in healthcare products. Their framing is careful. The case for change is not presented as lighter regulation, but as a way to improve speed and efficiency without lowering standards. That distinction matters in a sector where public trust is hard won and easily damaged. A regulator can only move more quickly if its evidence systems, governance arrangements and digital controls are strong enough to support that pace.
As an executive agency of the Department of Health and Social Care, the MHRA sits between government policy and day-to-day market oversight. Choices about digital systems may look administrative, but they shape how regulation is experienced by companies bringing products to market and by patients relying on the Agency’s judgement. If the programme described in the government statement is carried through, firms can expect more digitally managed interaction with the regulator and potentially clearer service pathways across medicines and device work. The public test will be whether those changes improve responsiveness without weakening accountability.
The immediate development is straightforward: one senior appointment, ahead of a new strategy period, with Bonander due to join in late May 2026. Even so, the language used by the MHRA makes the wider direction clear. The Agency now treats digital systems, data governance and technology leadership as part of modern regulation rather than a purely back-office function. That makes the appointment worth close attention. For the UK body responsible for ensuring medicines and medical devices are effective and acceptably safe, the measure of success will not be the hire itself, but whether that leadership produces services that are quicker to use, easier to scrutinise and trusted by the public.